Document is current
Any future updates will be listed below
-
Authors
Taylor, Samuel R. https://orcid.org/0000-0002-0926-9394
Falcone, John N.
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Goncalves, Marcus D. https://orcid.org/0000-0002-0784-9248
- License Information
-
More Information
Article History
Accepted: 29 April 2022
First Online: 25 May 2022
Competing interests
: L.C.C. is a founder, shareholder and member of the scientific advisory board of Agios Pharmaceuticals and a founder and former member of the scientific advisory board of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing novel therapies for cancer. L.C.C. has received research funding from Ravenna Pharmaceuticals outside the covered work. L.C.C. and M.D.G. are co-founders and shareholders of Faeth Therapeutics, which are developing dietary and pharmacologic therapies for cancer. M.D.G. has received speaking and/or consulting fees from Pfizer Inc., Novartis AG, Petra Pharmaceuticals, Scorpion Therapeutics and Faeth Therapeutics. M.D.G.’s laboratory has received financial support from Pfizer Inc. outside the covered work. All other authors report no competing interests.
